American Century Companies Inc. Sells 125,757 Shares of RxSight, Inc. (NASDAQ:RXST)

American Century Companies Inc. lowered its position in shares of RxSight, Inc. (NASDAQ:RXST) by 50.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,805 shares of the company’s stock after selling 125,757 shares during the period. American Century Companies Inc. owned 0.31% of RxSight worth $4,256,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of RXST. Quarry LP grew its position in shares of RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares in the last quarter. Private Trust Co. NA purchased a new position in RxSight during the fourth quarter worth about $34,000. Arcadia Investment Management Corp MI bought a new position in RxSight in the 4th quarter worth about $46,000. Harbor Investment Advisory LLC purchased a new stake in shares of RxSight in the 4th quarter valued at about $52,000. Finally, Global Retirement Partners LLC purchased a new stake in shares of RxSight in the 4th quarter valued at about $69,000. Institutional investors own 78.78% of the company’s stock.

RxSight Stock Performance

Shares of RXST opened at $16.26 on Friday. The company has a market capitalization of $658.38 million, a P/E ratio of -19.59 and a beta of 1.26. RxSight, Inc. has a fifty-two week low of $14.37 and a fifty-two week high of $66.54. The business’s 50-day moving average is $28.12 and its two-hundred day moving average is $37.90.

RxSight (NASDAQ:RXST) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.25). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The business had revenue of $40.21 million during the quarter, compared to analysts’ expectations of $40.23 million. Analysts forecast that RxSight, Inc. will post -0.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RXST shares. Needham & Company LLC restated a “buy” rating and issued a $43.00 price objective on shares of RxSight in a research report on Thursday. Bank of America reissued an “underperform” rating and issued a $22.00 price target (down previously from $36.00) on shares of RxSight in a report on Thursday. Stifel Nicolaus reduced their price target on shares of RxSight from $33.00 to $28.00 and set a “hold” rating on the stock in a research report on Wednesday, March 19th. Wells Fargo & Company decreased their price objective on shares of RxSight from $35.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Thursday. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $17.00 target price (down from $40.00) on shares of RxSight in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, RxSight presently has an average rating of “Hold” and an average target price of $43.78.

Insider Buying and Selling

In related news, Director Tamara Fountain sold 7,000 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total transaction of $179,970.00. Following the transaction, the director now directly owns 24,793 shares in the company, valued at approximately $637,428.03. The trade was a 22.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jesse Anderson Corley acquired 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average cost of $31.18 per share, with a total value of $44,992.74. Following the acquisition, the director now directly owns 1,443 shares of the company’s stock, valued at $44,992.74. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 9.36% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.